de Halleux F
Drugs. 1987;33 Suppl 2:114-9. doi: 10.2165/00003495-198700332-00021.
A multicentre study with 622 patients has been undertaken to evaluate the efficacy of cyclandelate 1600 mg daily in the treatment of vertigo of circulatory origin in general practice. The characteristics of the patient population were consistent with the diagnosis of vertigo of circulatory origin. Patients with some risk factors, essentially a history of thrombosis and atherosclerotic patients, had more severe symptoms at the onset of the study. During the 3-month period of treatment with cyclandelate, the average global score of vertigo (0-10) decreased from 5.57 to 2.12 and the average scores of frequency, severity and duration of vertigo (0-4) decreased from 2.53, 2.55 and 2.26 to 0.98, 0.89 and 0.84, respectively. Patients previously treated with other anti-ischaemic drugs had similar responses compared to other patients. These results indicate that cyclandelate may be useful in the management of vertigo of circulatory origin in general practice.
一项针对622名患者的多中心研究已开展，以评估每日服用1600毫克环扁桃酯在普通医疗中治疗循环系统源性眩晕的疗效。患者群体的特征与循环系统源性眩晕的诊断相符。有一些风险因素的患者，主要是有血栓形成病史的患者和动脉粥样硬化患者，在研究开始时症状更严重。在使用环扁桃酯治疗的3个月期间，眩晕的平均总体评分（0至10分）从5.57降至2.12，眩晕的频率、严重程度和持续时间的平均评分（0至4分）分别从2.53、2.55和2.26降至0.98、0.89和0.84。与其他患者相比，先前接受过其他抗缺血药物治疗的患者有类似的反应。这些结果表明，环扁桃酯在普通医疗中治疗循环系统源性眩晕可能有用。
